Binnopharm Group and China’s Mabwell have signed a MoU concerning localization of the production of dupilumab in Russia and the EAEU, The biopharmaceutical drug based on monoclonal antibodies is intended for the treatment of atopic dermatitis and bronchial asthma. This was reported to GxP News by the press service of the Russian group.
The MoU builds upon the successful partnership between the companies, which began in 2022 when Binnopharm Group obtained exclusive rights for the production, registration, and sale of Mabwell’s drugs – adalimumab and denosumab. The production facility for their manufacture at the site in Zelenograd has already been launched. Currently, validation batches of the active pharmaceutical ingredients (APIs) are being produced. The first drugs planned for the Russian market are those for the treatment of rheumatoid arthritis and osteoporosis. Obtaining marketing authorizations and launching the finished drugs on the market are scheduled for the beginning of 2026.
Statement by Rustem Muratov, General Director of Binnopharm Group:
“The successful implementation of current projects with Mabwell creates a solid foundation for considering new joint initiatives. Establishing a full-cycle production facility in Zelenograd – from cell line cultivation to purification, formulation, and finished dosage form production for the first two drugs – has demonstrated our ability to implement the most complex biopharmaceutical projects within short timeframes. We are starting work to study the possibility of localizing the next promising product – dupilumab – and are confident that our accumulated experience and established infrastructure will allow us to execute this project just as effectively.”
According to AlphaRM data, the annual sales volume of medicines containing the active substance dupilumab in the tender segment exceeds 5 billion rubles, placing it among the top 50 drugs by sales volume in rubles. Furthermore, growth for the first 9 months of 2025 in monetary terms amounted to 53% compared to the same period last year.